PDCD1 and melanoma: Pembrolizumab, an anti-PD-1 antibody was tested first in the neoadjuvant setting by Huang et al., using a single dose of pembrolizumab (200 mg) followed by complete resection three weeks later in 29 patients with stage III/IV resectable melanoma.